Strs Ohio increased its position in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 13,520,000.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 135,201 shares of the specialty pharmaceutical company’s stock after buying an additional 135,200 shares during the period. Strs Ohio’s holdings in Valeant Pharmaceuticals International were worth $2,346,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Morgan Stanley increased its position in Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock worth $30,631,000 after buying an additional 903,256 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in Valeant Pharmaceuticals International by 61.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 41,414 shares of the specialty pharmaceutical company’s stock worth $457,000 after buying an additional 15,719 shares in the last quarter. Gabelli Funds LLC bought a new position in Valeant Pharmaceuticals International during the first quarter worth $331,000. Bogle Investment Management L P DE bought a new position in Valeant Pharmaceuticals International during the first quarter worth $11,223,000. Finally, Guggenheim Capital LLC increased its position in Valeant Pharmaceuticals International by 18.6% in the fourth quarter. Guggenheim Capital LLC now owns 17,540 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 2,752 shares in the last quarter. Hedge funds and other institutional investors own 51.14% of the company’s stock.

Valeant Pharmaceuticals International, Inc. (NYSE VRX) opened at 14.07 on Thursday. Valeant Pharmaceuticals International, Inc. has a 1-year low of $8.31 and a 1-year high of $32.74. The company’s market cap is $4.90 billion. The firm’s 50-day moving average price is $16.61 and its 200-day moving average price is $13.38.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. The company had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. During the same quarter last year, the business posted ($0.88) earnings per share. The firm’s revenue was down 7.7% compared to the same quarter last year. Equities research analysts forecast that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Strs Ohio Has $2.35 Million Position in Valeant Pharmaceuticals International, Inc. (VRX)” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/strs-ohio-has-2-35-million-position-in-valeant-pharmaceuticals-international-inc-vrx/1467038.html.

VRX has been the subject of a number of analyst reports. Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a research note on Sunday, July 30th. BidaskClub downgraded Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research note on Friday, June 16th. Scotiabank decreased their price target on Valeant Pharmaceuticals International from $15.00 to $12.00 and set a “sector perform” rating for the company in a research note on Wednesday, April 26th. Vetr downgraded Valeant Pharmaceuticals International from a “strong-buy” rating to a “buy” rating and set a $14.82 price target for the company. in a research note on Monday, May 22nd. Finally, Mizuho restated an “underperform” rating and issued a $8.00 price target (down from $9.00) on shares of Valeant Pharmaceuticals International in a research note on Monday, April 17th. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and an average target price of $17.26.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.